MGMT and central nervous system cancer: The MGMT promoter methylation status was found to be an important indicator of chemosensitivity in gliomas, and the correlations between the risk score and MGMT promoter methylation status suggests that the former might be related to chemotherapeutic drug sensitivity (Fig. 3I–L).